Doctors believe TURP is the best surgery for enlarged prostate if they have the right training and equipment — but many rural areas don’t have access to it.
Scientific Claim
TURP is considered the treatment of choice for symptomatic benign prostatic hyperplasia when trained surgeons and facilities are available, despite limited access in rural areas.
Original Statement
“TURP is considered the gold standard in surgical management of BPH... TURP remains the treatment of choice provided trained surgeons and facilities are there.”
Evidence Quality Assessment
Claim Status
overstated
Study Design Support
Design cannot support claim
Appropriate Language Strength
association
Can only show association/correlation
Assessment Explanation
The study reports outcomes in 47 TURP patients only — it does not compare TURP to other treatments. Claiming it is 'the treatment of choice' implies superiority without evidence. The verb 'is' is definitive but unsupported by the study design.
More Accurate Statement
“TURP is regarded by clinicians as the standard surgical option for symptomatic benign prostatic hyperplasia when resources permit, though this study did not compare it to alternative treatments.”
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.
Systematic Review & Meta-AnalysisLevel 1aWhether TURP provides superior symptom relief, complication rates, or cost-effectiveness compared to HoLEP, PVP, or open prostatectomy.
Whether TURP provides superior symptom relief, complication rates, or cost-effectiveness compared to HoLEP, PVP, or open prostatectomy.
What This Would Prove
Whether TURP provides superior symptom relief, complication rates, or cost-effectiveness compared to HoLEP, PVP, or open prostatectomy.
Ideal Study Design
A meta-analysis of ≥10 RCTs comparing TURP to HoLEP, PVP, and open prostatectomy in men aged 60–80 with BPH and prostate volume 30–80g, using IPSS, Qmax, catheter time, hospital stay, and cost as primary outcomes.
Limitation: Cannot account for surgeon learning curves or regional resource disparities.
Randomized Controlled TrialLevel 1bWhether TURP is more effective or safer than HoLEP or PVP in the same patient population.
Whether TURP is more effective or safer than HoLEP or PVP in the same patient population.
What This Would Prove
Whether TURP is more effective or safer than HoLEP or PVP in the same patient population.
Ideal Study Design
A multicenter double-blind RCT of 300+ men aged 60–80 with BPH, randomized to TURP vs HoLEP vs PVP, with primary outcome: IPSS reduction at 12 months, secondary: transfusion rate, reoperation, cost.
Limitation: Blinding is impossible in surgical trials; surgeon skill may confound results.
Prospective Cohort StudyLevel 2bReal-world comparative outcomes of TURP versus other procedures in routine practice.
Real-world comparative outcomes of TURP versus other procedures in routine practice.
What This Would Prove
Real-world comparative outcomes of TURP versus other procedures in routine practice.
Ideal Study Design
A prospective cohort study comparing 200 TURP patients to 200 HoLEP/PVP patients matched for age, prostate size, and comorbidities, tracking outcomes over 2 years in a real-world setting.
Limitation: Selection bias likely; patients may be assigned based on availability, not randomization.
Evidence from Studies
Supporting (1)
This study shows that TURP works well and is the best surgery for enlarged prostates when doctors and hospitals have the right tools — even in rural areas. It agrees with the claim that TURP should be the top choice if it’s available.